News Express: ZUMRI, Liuyao Group inaugurate joint laboratory
新聞快訊：珠研院與柳藥集團聯合實驗室揭牌
揭牌儀式
The plaque unveiling ceremony
珠研院與柳藥集團聯合實驗室揭牌
珠海澳大科技研究院 — 廣西柳藥集團股份有限公司聯合實驗室於今（5）日舉行揭牌儀式，標誌著珠研院與柳藥集團在中醫藥研發及產業化方面達成戰略合作。雙方將聯手加快中醫藥產業技術進步，推進產業結構升級，爲澳門中醫藥產業發展和深合區建設作出貢獻。
澳門大學中華醫藥研究院院長、中藥質量研究國家重點實驗室代主任陳新表示，澳大作爲國際化綜合性公立大學，澳大中華醫藥研究院肩負着傳承和發展中醫藥文化的責任；澳大中藥質量研究國家重點實驗室已在產業合作、國際合作平台、中藥標準化、國際化等領域取得顯著成果；柳藥集團作爲享譽市場的知名醫藥企業，其豐厚資源積累將助力聯合實驗室的高質量發展。聯合實驗室的成立進一步提升深合區在國家醫療科技發展和對外開放中的支撐引領作用，讓更多粵澳科技力量參與國家戰略建設。
澳大研究服務及知識轉移辦公室代主任、珠海澳大科技研究院副院長王春明表示，珠研院作爲澳大的產學研示範基地，依託澳大中藥質量研究國家重點實驗室的研發實力，堅持不懈促進中醫藥產業技術研究與轉化應用；共建聯合實驗室將有力推動中醫藥領域的優勢資源實現有機融合，產生協同效應，爲廣大居民帶來更多健康福祉。
廣西柳藥集團股份有限公司董事長朱朝陽表示，聯合實驗室的成立能夠推動研究創新成果更好地賦能產業發展；柳藥集團70年深耕於大醫藥健康領域，自主創新培育出一系列中藥材優勢產品；是次合作是柳藥集團與珠研院戰略合作的具體體現，雙方將共同推進粵澳桂三地中醫藥產業發展，樹立長效產學研合作機制標杆。
澳門中藥研發中心主任、中藥質量研究國家重點實驗室（澳門大學）創始主任王一濤在專題分享和媒體採訪中表示，澳大中華醫藥研究院致力創造傳承創新的中醫藥研究和開發成果，研究院和國家重點實驗室聚焦中藥質量有效、安全、穩定、可控等核心要素的同時，積極把握多項政策帶來的新機遇，善用澳門一國兩制的國際位勢，創造了豐碩成果；珠研院下設的中華醫藥研發中心有效助推研究創新成果轉化，相信與柳藥集團等知名藥企合作能促進產學研協同創新發展，加速驅動中醫藥的科技創新發展，助力澳門產業多元化發展及中醫藥產業轉型升級，有效拓展東盟國家、“一帶一路”延線國家、葡語系國家等海外市場，提高中醫藥產業的國際影響力。
橫琴粵澳深度合作區經濟發展局科技和人才處副處長余超，澳門中藥研發中心副主任兼中藥質量研究國家重點實驗室（澳門大學）項目主任王勝鵬，廣西柳藥集團股份有限公司常務副總裁朱仙華和品牌推廣部部長李玉生，廣西柳藥創新醫藥研究有限公司總經理歐彪和項目經理何翊亦出席了揭牌儀式。
欲瀏覽官網版可登入以下連結:
https://www.um.edu.mo/zh-hant/news-and-press-releases/campus-news/detail/55957/
ZUMRI, Liuyao Group inaugurate joint laboratory
Zhuhai UM Science & Technology Research Institute (ZUMRI) and Guangxi Liuyao Group Co Ltd today (5 July) held a plaque unveiling ceremony for their joint laboratory, which marked the strategic cooperation between ZUMRI and Liuyao Group in the research, development, and commercialisation of Chinese medicine. The two parties will work together to accelerate the technological progress of the Chinese medicine industry, promote the upgrading of the industrial structure, and contribute to the development of the Chinese medicine industry in Macao and the development of the Guangdong-Macao In-depth Cooperation Zone in Hengqin.
Chen Xin, director of UM’s Institute of Chinese Medical Sciences and interim director of the State Key Laboratory of Quality Research in Chinese Medicine (SKL-QRCM), said that the establishment of the joint laboratory will strengthen the supporting and leading role of the Cooperation Zone in medical technology development and opening-up of the country, which will enable more practitioners in science and technology from Guangdong and Macao to be involved in the country’s strategic development. Wang Chunming, interim director of UM’s Research Services and Knowledge Transfer Office and deputy director of ZUMRI, said that the joint laboratory will promote the organic integration of advantageous resources in the field of Chinese medicine and benefit the well-being of the general public. Zhu Chaoyang, chairman of Guangxi Liuyao Group Co Ltd, said that the establishment of the joint laboratory will promote innovative research results to empower industrial development, adding that the joint laboratory is a manifestation of the strategic cooperation between ZUMRI and Liuyao Group, which will facilitate the development of the Chinese medicine industry in Guangdong, Macao, and Guangxi and set a benchmark for industry-academia collaboration. Wang Yitao, director of the Macao Centre for Research and Development in Chinese Medicine and founding director of SKL-QRCM, said during the panel discussion and media interview that the cooperation between ZUMRI and Liuyao Group willaccelerate the technological innovation in Chinese medicine to promote the industrial diversification of Macao and the transformation and upgrading of the Chinese medicine industry, and enhance the international influence of the Chinese medicine industry.
To read the news on UM’s official website, please visit the following link:
https://www.um.edu.mo/news-and-press-releases/campus-news/detail/55957/